OGEN News and Press, Oragenics Inc. From 11/13/19

Clinical Differentiation And Gap Oragenics Inc. ( OGEN ) is a small-cap ($21M) clinical-stage company developing innovative therapies for SOM and infectious diseases. Focusing on SOM associated with head and neck cancer (HNC.) radiotherapy, Phase 2 investigative drug candidate AGO13 was i...

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the company’s Senior Vice President of Discovery Research, Martin Handfield, MS, Ph.D., will be a featured spea...

The following slide deck was published by Oragenics, Inc. in conjunction with this Read more ...

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will be presenting at the BIO Investor Forum in San Francisco. The company will present to investors on Oct...

Oragenics, Inc. (NYSE American:OGEN) (“Oragenics”), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initial data from its ongoing Phase 2, placebo-controlled, clinical trial of AG013 in ora...

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces it has enrolled 158 patients in its Phase 2 trial of AG013 for the treatment of severe oral mucositis. In addition...

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces that an abstract from its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of AG...

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced that Alan Joslyn, president and CEO of Oragenics, Inc. will be a featured presenter at the 21 st ...

(Source - Pexels ) An increasing number of brokerages are allowing individual investors to take part in lending their long positions to short sellers for extra returns from short sellers ' interest payments. This is also known as a "Stock Yield Enhancement Program" or SYEP. In the cas...

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces it will be presenting a talk titled “Lantibiotics, a Novel Class of Antibiotics in the Pha...